pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Demographic and baseline characteristics of the study population (n=149)

All Proteinuria (n=29) Non-proteinuria (n=120) p-value
Gender, n (%) 0.90
Male 91 (61.1) 18 (62.1) 73 (60.8)
Female 58 (38.9) 11 (37.9) 47 (39.2)
Age, years* 61.7 ± 10.3 62.6 ± 10.5 61.5 ± 10.3 0.62
Primary site, n (%) 0.73
Colon 78 (52.4) 16 (55.2) 62 (51.7)
Rectal 71 (47.7) 13 (44.8) 58 (48.3)
Recurrence, n (%) 0.85
No 64 (43.0) 12 (41.4) 52 (43.3)
Yes 85 (57.1) 17 (58.6) 68 (56.7)
Organs metastasized
Lung 74 (49.7) 14 (48.3) 60 (50.0) 0.87
Liver 72 (48.3) 16 (55.2) 56 (46.7) 0.41
Brain 1 (0.7) 0 (0.0) 1 (0.8) 1.00*
Bone 11 (7.4) 0 (0.0) 11 (9.2) 0.12*
Other organs 32 (21.5) 7 (24.1) 25 (20.8) 0.70
Surgery 0.49*
No 15 (10.1) 4 (13.8) 11 (9.2)
Yes 134 (89.9) 25 (86.2) 109 (90.8)
Radiation therapy 0.77
No 96 (64.4) 18 (62.1) 78 (65.0)
Yes 53 (35.6) 11 (20.8) 42 (35.0)
Number of protocol administrations including Bevacizumab
8.9 ± 3.7 8.5 ± 3.6 8.9 ± 3.7 0.54
Chemotherapy with bevacizumab 0.10*
Capecitabine + bevacizumab 2 (1.3) 2 (6.9) 0 (0.0)
FL + bevacizumab 8 (5.4) 1 (3.5) 7 (5.8)
FOLFIRI + bevacizumab 92 (61.7) 17 (58.6) 75 (62.5)
FOLFOX + bevacizumab 47 (31.5) 9 (31.0) 38 (31.7)
Previous adjuvant chemotherapy 0.71
No 40 (26.9) 7 (24.1) 33 (27.5)
Yes 109 (73.2) 22 (75.9) 87 (72.5)
Previous adjuvant chemotherapy including Bevacizumab 0.11
No 123 (82.6) 21 (72.4) 102 (85.0)
Yes 26 (17.5) 8 (27.6) 18 (15.0)

Data are expressed as numbers (%) of patients or as mean ± standard deviation (SD).

Chi-square test

* Fischer's exact test

FL: 5-Fluorouracil, leucovorin, FOLFIRI: 5-Fluorouracil, leucovorin, irinotecan, FOLFOX: 5-Fluorouracil, leucovorin, oxaliplatin

Korean J Clin Pharm 2020;30:234-42 https://doi.org/10.24304/kjcp.2020.30.4.234
© 2020 Korean J Clin Pharm